A Triple‐Responsive Polymeric Prodrug Nanoplatform with Extracellular ROS Consumption and Intracellular H 2 O 2 Self‐Generation for Imaging‐Guided Tumor Chemo‐Ferroptosis‐Immunotherapy
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202303568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Yongjuan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China. Hauptthemen laut MEDLINE: Hydrogen Peroxide, Prodrugs, Ferroptosis, Reactive Oxygen Species. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Start-up Grant from Zhengzhou University.
Abstract (Originalsprache)
High reactive oxygen species (ROS) levels in tumor microenvironment (TME) impair both immunogenic cell death (ICD) efficacy and T cell activity. Furthermore, tumor escapes immunosurveillance via programmed death‐1/programmed death ligand‐1 (PD‐L1) signal, and the insufficient intracellular hydrogen peroxide weakens ferroptosis efficacy. To tackle the above issues, a glutathione (GSH)/ROS/pH triple‐responsive prodrug nanomedicine that encapsulates Fe 2 O 3 nanoparticle via electrostatic interaction is constructed for magnetic resonance imaging (MRI)‐guided multi‐mode theranostics with chemotherapy/ferroptosis/immunotherapy. The diselenide bond consumes ROS in TME to increase T cells and ICD efficacy, the cleavage of which facilitates PD‐L1 antagonist D peptide release to block immune checkpoint. After intracellular internalization, Fe 2 O 3 nanoparticle is released in the acidic endosome for MRI simultaneously with lipid peroxides generation for tumor ferroptosis. Doxorubicin is cleaved from polymers in the condition of high intracellular GSH level accompanied by tumor ICD, which simultaneously potentiates ferroptosis by NADPH oxidase mediated H 2 O 2 self‐generation. In vivo results indicate that the nanoplatform strengthens tumor ICD, induces cytotoxic T lymphocytes proliferation, inhibits 4T1 tumor regression and metastasis, and prolongs survival median. In all, a new strategy is proposed in strengthening ICD and T cells activity cascade with ferroptosis as well as immune checkpoint blockade for effective tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- The center of Infection and Immunity, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), Singapore, 138673.
- Zhengzhou University, Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou, Henan, 450001, China.
ORCID-Profile: Weijing Yang
Förderung
- National Natural Science Foundation of China
- Start-up Grant from Zhengzhou University
Zitieren
APA
Li, Y., Cao, Y., Ma, K., Ma, R., Zhang, M., Guo, Y., Song, H., Sun, N., Zhang, Z., & Yang, W. (2024). A Triple‐Responsive Polymeric Prodrug Nanoplatform with Extracellular ROS Consumption and Intracellular H 2 O 2 Self‐Generation for Imaging‐Guided Tumor Chemo‐Ferroptosis‐Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202303568
Vancouver
Li Y, Cao Y, Ma K, Ma R, Zhang M, Guo Y, et al. A Triple‐Responsive Polymeric Prodrug Nanoplatform with Extracellular ROS Consumption and Intracellular H 2 O 2 Self‐Generation for Imaging‐Guided Tumor Chemo‐Ferroptosis‐Immunotherapy. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202303568
BibTeX
@article{Li2024,
author = {Li, Yongjuan and Cao, Yongjian and Ma, Kunru and Ma, Rong and Zhang, Mengzhe and Guo, Yichen and Song, Haiwei and Sun, Nannan and Zhang, Zhenzhong and Yang, Weijing},
title = {A Triple‐Responsive Polymeric Prodrug Nanoplatform with Extracellular ROS Consumption and Intracellular H 2 O 2 Self‐Generation for Imaging‐Guided Tumor Chemo‐Ferroptosis‐Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202303568}
}
EUVIMED